Dr. Reddy's Laboratories Limited (RDY)
Automate Your Wheel Strategy on RDY
With Tiblio's Option Bot, you can configure your own wheel strategy including RDY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RDY
- Rev/Share 373.5748
- Book/Share 385.8871
- PB 3.2976
- Debt/Equity 0.1608
- CurrentRatio 1.9175
- ROIC 0.1315
- MktCap 1047455179784.1
- FreeCF/Share 7.8206
- PFCF 160.7266
- PE 19.5191
- Debt/Assets 0.1062
- DivYield 0.0065
- ROE 0.1792
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | RDY | Nomura | Buy | Neutral | -- | -- | Dec. 19, 2024 |
News
Dr. Reddy's Continues To Be A Good Buy At Current Valuation
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Positive
I reiterate my strong buy rating on Dr. Reddy's Laboratories due to its attractive valuation and underappreciated growth potential beyond Revlimid. Recent results exceeded expectations, with 20% YoY revenue growth driven by acquisitions and strong performance in generics, especially in Europe and India. While Revlimid's patent expiry poses a headwind, RDY's robust pipeline in biosimilars and GLP-1s should offset revenue declines and support long-term growth.
Read More
RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Dr. Reddy's stock is up on encouraging fiscal fourth-quarter 2025 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.
Read More
Dr. Reddy's Q4 & Full Year FY25 Financial Results
Published: May 09, 2025 by: Business Wire
Sentiment: Neutral
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter and year ended March 31, 2025.
Read More
Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia
Published: March 27, 2025 by: PRNewsWire
Sentiment: Neutral
GUANGZHOU, China and HYDERABAD, India , March 27, 2025 /PRNewswire/ -- Bio-Thera Solutions (688177:SH; "Bio-Thera"), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as "Dr. Reddy's"), announce today they have reached commercialization and license agreements for BAT2206, a proposed Stelara® biosimilar, and BAT2506, a proposed Simponi® biosimilar.
Read More
FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for Review
Published: March 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Dr. Reddy and Alvotech announce the FDA acceptance of the BLA for their proposed biosimilar candidate of Amgen's Prolia and Xgeva for review.
Read More
Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag
Published: March 13, 2025 by: Business Wire
Sentiment: Neutral
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDYS--Dr. Reddy's issues a nationwide recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, due to mislabeling of infusion bag.
Read More
About Dr. Reddy's Laboratories Limited (RDY)
- IPO Date 2001-04-11
- Website https://www.drreddys.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Mr. Erez Israeli M.B.A.
- Employees 27048